ConvaTec (GB:CTEC)
LSE:CTEC
CTEC Stock Chart & Stats
218.60 p
1.06 p(0.47%)
At close: 4:00 PM EST
218.60 p
1.06 p(0.47%)
Day’s Range― - ―
52-Week Range209.40 p - 311.20 p
Previous CloseN/A
Volume85.46K
Average Volume (3M)6.27M
Market Cap
£4.26B
Enterprise Value7.19B
Total Cash (Recent Filing)£75.03M
Total Debt (Recent Filing)£1.61B
Price to Earnings (P/E)37.1
Beta0.94
Next Earnings
Aug 04, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.11%
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.34
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£321.70Price Target Upside47.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.57B
Bulls Say, Bears Say
Bulls Say
Recurring Consumable Revenue ModelConvaTec’s core business sells repeat-purchase consumables across wound, ostomy, continence and infusion care. That recurring revenue mix produces predictable demand, strong customer stickiness via clinical relationships and reimbursement pathways, supporting stable cash flows and margins over time.
Consistent Multi-year Organic GrowthFive straight years of organic growth and guidance of 5–7% for 2026 (with a medium-term 6–8% target) indicate durable end-market demand and successful product adoption. Multi-year growth supports investment payback, scale benefits and helps sustain operating leverage as new launches gain traction across markets.
Strong Cash Generation And ReturnsRobust free cash flow with >100% conversion and active capital returns (buyback and dividend increases) demonstrate high cash conversion capacity. Reliable FCF funds growth CapEx and pipeline spend while enabling shareholder returns and optionality for deleveraging or selective M&A without eroding operational funding.
Bears Say
InnovaMatrix Reimbursement ShockA CMS-driven ~80% price reduction and $72m impairment reveal material vulnerability to payor policy for an acquired product. This reimbursement shock creates a sustained revenue and margin headwind, introduces channel/legal uncertainty, and shows acquisitions reliant on reimbursement can rapidly deteriorate value.
FDA Warning Letter On Quality SystemsAn FDA warning on complaints/CAPA points to systemic quality and compliance gaps. Remediation can be resource intensive, slow product launches, increase inspection frequency and hurt provider confidence. Persistent process issues risk regulatory constraints that could limit growth in key regulated channels over months to years.
Rising Leverage And Working CapitalLeverage increased notably, reducing financial flexibility and heightening sensitivity to earnings or rate shocks even as management targets ~2x net debt/EBITDA. Higher working capital and elevated growth CapEx needs may keep leverage elevated, constraining ability to fund large initiatives or absorb cyclical stress without extra financing.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 209.40 p and its highest was 311.20 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £4.26B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 127 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported 0.073 p earnings per share for the quarter, missing the consensus estimate of 0.075 p by -0.002 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 1.399 p which represents an annual dividend yield of 2.11%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.07.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.073 p in its last earnings report, missing expectations of 0.075 p. Following the earnings report the stock price went up 10.396%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£321.70 (47.16% Upside)
£321.70 (47.16% Upside)
Insider Transactions
Sold Shares
Worth £747.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
10.53%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
321.70 p
▲(47.16% Upside)
Technical Analysis
Options Prices
Currently, No data available
---